Skip to main content
. 2020 May 20;4:PO.19.00298. doi: 10.1200/PO.19.00298

FIG 3.

FIG 3.

Survival plot for BRAF V600E–mutated pediatric low-grade gliomas (PLGGs). Progression-free survival (PFS) for (A) 56 patients with PLGG treated with BRAF inhibition, (B) those in whom BRAF inhibition therapy was continued for ≥ 10 months, and (C) those in whom BRAF inhibition was discontinued after ≥ 10 months. (D) PFS for patients with BRAF V600E–mutated PLGG treated with chemotherapy.